Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc. Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy Xyphos shareholders to receive up to $665 million in structured, milestone-based acquisition PR Newswire TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 TOKYO and SOUTH SAN FRANCISCO, Calif […]